Human Pro–B-Type Natriuretic Peptide Is Processed in the Circulation in a Rat Model

Semenov, Alexander G.; Seferian, Karina R.; Tamm, Natalia N.; Артемьева, М.М.; Postnikov, Alexander B.; Bereznikova, A.; Kara, Andrey N.; Na, Medvedeva; Katrukha, Alexey G.

doi:10.1373/clinchem.2010.161125

Cited by 30 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unprocessed proBNP, however, exhibits markedly reduced physiological activity compared with BNP and is currently considered to be insufficient to promote an adequate physiological natriuretic hormone response in HF patients (6 ). Our previous studies in rats have revealed that processing of proBNP in the circulation is possible (33 ). Given this, the influence of LCZ696 on the efficiency of proBNP processing, giving rise to bioactive BNP, appears also to be important to evaluate.…”

Section: Discussionmentioning

confidence: 99%

Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter

Semenov

Katrukha

2016

Clinical Chemistry

Self Cite

View full text Add to dashboard Cite

BACKGROUND:Protease neprilysin is known to be responsible for the degradation of natriuretic peptides. A recent heart failure (HF) drug, LCZ696 (Entresto TM ), that combines a neprilysin inhibitor and an angiotensin II receptor inhibitor was suggested to augment circulating B-type natriuretic peptide (BNP) concentrations, making the results of BNP measurements diagnostically ambiguous. Because the main form of measured BNP in HF patients is represented by its uncleaved precursor, proBNP, it is important to know the susceptibility of proBNP to cleavage by neprilysin.

show abstract

Section: Discussionmentioning

confidence: 99%

Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter

Semenov

Katrukha

2016

Clinical Chemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…The relatively high circulating concentrations of proBNP in patients with heart failure have led to speculation that proBNP may be processed in blood or tissues to provide an additional supply of circulating or tissue BNP [78,93,94]. This speculation is supported by results from two studies.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

B-type Natriuretic Peptide circulating forms: Analytical and bioactivity issues

Yandle

Richards

2015

Clinica Chimica Acta

View full text Add to dashboard Cite

“…In the control group (n=3), animals were treated with the vehicle solution (intravenously). In the treated group (n=3), animals were treated (intravenously) with 12 nmol/kg of human BNP (hBNP) (Genscript, NJ), at a dose that has been previously demonstrated to increase the endogenous levels of BNP in rats 24. For BNP dissolution, powder was dissolved in a minimal amount of 50 mmol/L Na‐acetate buffer, and then resuspended in saline, and the pH was adjusted to 7.4. hBNP concentration was adjusted to inject 1 mL of treatment per animal.…”

Section: Methodsmentioning

confidence: 99%

Heads and Tails of Natriuretic Peptides: Neuroprotective Role of Brain Natriuretic Peptide

Fernández-Susavila

Rodríguez‐Yáñez

Dopico-López

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundBesides the relevant role of brain‐type natriuretic peptide (BNP) as biomarker of cardioembolic strokes, new experimental evidences suggest that this peptide may mediate neuroprotective effects. In this study, we have evaluated for the first time the clinical association between BNP (by means of proBNP) and good outcome in ischemic stroke patients, and analyzed the effect of blood BNP increase in an ischemic animal model.Methods and ResultsA retrospective study with 2 different cohorts (262 patients in cohort I and 610 in cohort II) from the same prospective stroke registry was performed. proBNP concentration was analyzed within the first 12 hours from stroke onset. The primary predictor variable was functional outcome evaluated by modified Rankin Scale at 3 months. For the experimental study, BNP pretreatment was tested in an ischemic animal model subjected to a transient occlusion of the cerebral artery, and the infarct volume and sensorimotor deficit were evaluated for 14 days. Cardioembolic strokes presented a positive correlation between proBNP concentration and modified Rankin Scale at 3 months; however, noncardioembolic strokes presented a negative correlation. In the logistic regression analysis, noncardioembolic strokes with concentrations of proBNP ≥340 pg/mL were associated with a good outcome. In line with these clinical findings, the experimental study revealed that those BNP pretreated animals presented a reduction on infarct volumes at 24 hours and functional recovery at days 7 and 14 compared with the control groups.ConclusionsThese clinical and experimental evidences support the potential role of BNP as a protective factor against cerebral ischemia.

show abstract

Human Pro–B-Type Natriuretic Peptide Is Processed in the Circulation in a Rat Model

Cited by 30 publications

References 33 publications

Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter

Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter

B-type Natriuretic Peptide circulating forms: Analytical and bioactivity issues

Heads and Tails of Natriuretic Peptides: Neuroprotective Role of Brain Natriuretic Peptide

Contact Info

Product

Resources

About